Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company's proprietary CONNECT platform enables discovery of novel targets emerging from cellular interaction networks rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/18/26	$4,750,000	Seed	Dementia Discovery Fund LifeSpan Vision Ventures Mass General Brigham Ventures Ono Venture Investment UTEC	undisclosed